IP Library Granted Patent US 10,130,736
Granted Patent B1
US 10,130,736 · App. 14/933,176 · Granted Nov 20, 2018

Tissue-derived tissuegenic implants, and methods of fabricating and using same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,130,736
App. No.
14/933,176
Granted
Nov 20, 2018
Kind
B1
Abstract

The disclosure provides implants containing a plurality of particles containing at least one population of viable osteogenic cells adherent to and resident in an osteoconductive matrix or at least one viable population of osteogenic cells caused to be in contact with the osteoconductive matrix; methods of fabricating the implants; and use of the implants in bone repair. The implant further contains an osteoinductive component. An example of an osteoinductive component is a demineralized bone matrix in the form of particles or fibers.

Claims (15)

1. A composition for implantation in a patient, consisting essentially of:

cancellous bone particles, wherein the cancellous bone particles have osteoconductive properties;

wherein the cancellous bone particles have viable endogenous osteogenic cells; and

demineralized cortical bone fibers, wherein the demineralized cortical bone fibers have osteoinductive properties;

wherein a sufficient amount of the demineralized cortical bone fibers results in the composition having improved cohesion compared to a composition consisting of less than a sufficient amount of demineralized cortical bone fibers and no other carrier.

2. The composition according to claim 1 , wherein the demineralized bone fibers have elongated shapes.

3. The composition according to claim 2 , wherein the demineralized bone fibers have a maximum dimension in a range of about 1 mm to about 10 mm before demineralization.

4. The composition according to claim 3 , wherein the maximum dimension of the demineralized bone fibers is about 6 mm, about 7 mm, about 8 mm or about 9 mm before demineralization.

5. The composition according to claim 3 , wherein the demineralized bone fibers have a minimum dimension in a range of about 5 μm to about 300 μm before demineralization.

6. The composition according to claim 1 , wherein the demineralized bone fibers are mixed with the cancellous bone particles in a ratio of about 60% demineralized bone fibers to about 40% cancellous bone particles.

7. The composition according to claim 1 , wherein the demineralized bone fibers are allogeneic to the patient.

8. The composition according to claim 1 , wherein the cancellous bone particles and the demineralized bone fibers are allogeneic to the patient.

9. The composition according to claim 1 , wherein the composition is osteogenic and is not immunologically reactive after implantation in the patient.

10. The composition according to claim 1 , wherein the endogenous osteogenic cells include a population of viable osteoprogenitor cells.

11. The composition according to claim 1 , wherein the endogenous osteogenic cells are immune privileged.

Assignments (3)
SECURITY INTEREST Recorded Jul 27, 2023
From: MUSCULOSKELETAL TRANSPLANT FOUNDATION, INC.
To: M&T BANK
Reel/Frame 064401/0369 →
SECURITY INTEREST Recorded Dec 23, 2020
From: MUSCULOSKELETAL TRANSPLANT FOUNDATION, INC.
To: M&T BANK
Reel/Frame 054842/0458 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 7, 2017
From: SEMLER, ERIC; CALLAHAN, ALEX; CANALES, JOED; CARROLL, KATRINA; DASGUPTA, ANOUSKA; SHIKHANOVICH, ROMAN
To: MUSCULOSKELETAL TRANSPLANT FOUNDATION
Reel/Frame 041487/0557 →